Mayo Clinic | Strategic Alliance Partners

June 23, 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

June 11, 2015

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

May 19, 2015

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

May 19, 2015

By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

May 08, 2015

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.

March 31, 2015

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

March 31, 2015

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.

February 24, 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

February 14, 2015

Adverse events among patients with metastatic colorectal cancer who responded best to regorafenib in the phase III CORRECT trial were "broadly similar" to the overall study population.

January 27, 2015

Coping with challenges is part of the human condition, but self-awareness can have far-reaching results. Just ask Edith A. Perez, MD, about her experience attending medical school.

January 22, 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

July 23, 2014

Sean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.

June 09, 2014

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

May 15, 2014

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

April 08, 2014

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.

March 31, 2014

The role of allogeneic transplant in the treatment of adult patients with acute lymphoblastic leukemia (ALL) is evolving as a result of new studies providing evidence of the efficacy of an improved chemotherapy regimen

March 27, 2014

Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia

March 06, 2014

As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.

February 27, 2014

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

January 23, 2014

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.